Navigation Links
Cadila Pharmaceuticals Launches Joint Venture With Novavax in India
Date:7/9/2009

time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks relating to regulatory requirements in India, continued capitalization of the joint venture, facility construction and product development proceeding as planned, the early stage of product candidates under development; current results may not be predictive of future pandemic results, results of our seasonal influenza vaccine or any other vaccine that we may develop; further testing is required before regulatory approval can be applied for and the FDA may not approve a vaccine even if further trial results are similar to those disclosed previously by the company; uncertainties relating to clinical trials; dependence on the efforts of third parties; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility; and risks that we may lack the financial resources and access to capital to fund our operations including further clinical trials. Further information on the factors and risks that could affect Novavax's business, financial conditions and results of operations, is contained in Novavax's filings with the U.S. Securities and Exchange Commission, which are available at http://www.sec.gov. These forward-looking statements speak only as of the date of this press release, and Novavax assumes no duty to update forward-looking statements.


'/>"/>
SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
2. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
3. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
7. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
8. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
9. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
10. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
11. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... 2015 /PRNewswire/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced ... Resverlogix have approved the resolutions relating to: (i) ... 5,600,000 units at a price of $2.67 per ... comprised of one common share and 0.075358 common ... CAD$15 million; and (ii) the amendment to Resverlogix,s ...
(Date:6/30/2015)... 2015  NASA astronaut Kjell Lindgren , who is ... first mission to the International Space Station , will ... a.m. EDT Tuesday, July 7. Lindgren will participate ... Russia . The interviews will be preceded at ... mission training. To schedule an interview, media must ...
(Date:6/30/2015)... Americord Registry, one of the fastest growing cord blood banks ... at Kirkland & Ellis LLP, as the newest member of ...   "We are thrilled about Andrew Horne,s ... , CEO of Americord. "He brings a wealth of knowledge ... growth and vision." Andrew Horne is ...
(Date:6/30/2015)... Kent, WA (PRWEB) , ... June 30, 2015 ... ... offers a hydrophilic filter that does not sacrifice selectivity to achieve faster flow ... construction combines extremely fine pores with significant open space to allow easy liquid ...
Breaking Biology Technology:Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 3NASA Astronaut Preps for First Space Station Mission, Available for Media Interviews 2Americord Registry Announces Andrew Horne as Advisory Board Member 2New Nanofiber Membrane Provides Fast, Efficient Filtration 2
... Multiporator / Electroporator 2510 , , , , , , , ... Protocol No. 4308 915.521 02/2002 , , , ... , Microorganism , ... Cell type , Bacteria, gram positive, , ...
... , , , , Multiporator / Electroporator 2510 , , , ... Transformation Protocol , Protocol No. 4308 915.514 04/2002 , ... , , , , ... , Cell type , Bacteria, ...
... , , , , Multiporator / Electroporator 2510 , , , ... Transformation Protocol , Protocol No. 4308 915.511 04/2002 , ... , , , , ... , Cell type , Bacteria, gram ...
Cached Biology Technology:Mycobacterium intracellulare 2Escherichia coli K12 2Escherichia coli K12 3Escherichia coli C600 2Escherichia coli C600 3
(Date:6/23/2015)... GARDENS, Fla. , June 23, 2015 ... identity management and authentication solutions, today announced enhanced ... strong, multi-factor authentication solution.  The enhancements build ... use of the DigitalPersona Altus platform and ... reader compatibility. In today,s environment ...
(Date:6/17/2015)... GERMANTOWN, Maryland , June 17, 2015 ...   Produktlinie mit DNA-Tests verbessert den Analyseprozess und ... QGEN ; Frankfurt Prime Standard: QIA) hat heute in ... Produktlinie Investigator ® für ... Die neuen Kits zur Erstellung genetischer Fingerabdrücke bieten eine ...
(Date:6/17/2015)... , June 17, 2015  Crossmatch™, a leading ... that its U.are.U ® 4500 fingerprint readers ... Eateries, Inc., a San Jose, ... to increase security, improve accountability and reduce fraud ... instant, non-repudiable identity confirmation for employee sign in ...
Breaking Biology News(10 mins):Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 3QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 4QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 5QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 6Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 2Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 3
... ARBOR, Mich. An early laboratory success is taking ... gland transplants that could one day prevent a currently ... The scientists were able to induce embryonic stem ... hormone essential to maintaining bone density. The laboratory results ...
... ANN ARBOR, Mich.---Brain implants that can more clearly record ... at the University of Michigan. The findings could eventually ... as Parkinson,s disease and paralysis. Neural electrodes must ... When the electrodes are implanted, the brain first reacts ...
... calling on Congress to support the Consistency, Accuracy, Responsibility ... (CARE bill), which would ensure that states set minimum ... bill (H.R. 3652) was introduced Sept. 28 in the ... "The introduction of the CARE bill ...
Cached Biology News:Stem cell success points to way to regenerate parathyroid glands 2A step toward better brain implants using conducting polymer nanotubes 2A step toward better brain implants using conducting polymer nanotubes 3SNM urges Congress to support CARE bill 2
Mouse monoclonal antibody raised against a partial recombinant STAU2. NCBI Entrez Gene ID = STAU2...
...
Mouse polyclonal antibody to NR2F2 - nuclear receptor subfamily 2, group F, member 2...
... Pack provides optimized blocking and wash ... Clarifier: Ready-to-use wash solutions have been ... Coated Slides for Microarrays (Product Code ... Buffer: 1L • Microarray Post Hybridization ...
Biology Products: